XML 51 R40.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Other current assets | AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Receivables from counterparty $ 80   $ 52
Other current assets | Eisai      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Receivables from counterparty 75   71
Other current assets | Bayer AG      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Receivables from counterparty 33   32
Accounts payable and accrued liabilities | AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Payables to counterparty 584   405
Accounts payable and accrued liabilities | Eisai      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Payables to counterparty 557   375
Other noncurrent liabilities | AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Payables to counterparty 0   250
Other noncurrent liabilities | Eisai      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Payables to counterparty 325   543
Other noncurrent liabilities | Bayer AG      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Payables to counterparty 375   $ 375
Revenue | AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total sales 79 $ 33  
Revenue | Eisai      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total sales 74 0  
Revenue | Bayer AG      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Net product sales recorded by Merck 48 43  
Merck’s profit share from sales in Bayer’s marketing territories 42 25  
Total sales 90 68  
Cost of sales | AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 19 12  
Cost of sales | Eisai      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 51 0  
Cost of sales | Bayer AG      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 29 27  
Selling, general and administrative | AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 27 7  
Selling, general and administrative | Eisai      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 19 0  
Selling, general and administrative | Bayer AG      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 8 8  
Research and development | AstraZeneca      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 45 29  
Research and development | Eisai      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses 47 1,400  
Research and development | Bayer AG      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Expenses $ 30 $ 28